Approved Study Database
| Ref. No. | Scientific Title | Principal investigator |
|---|---|---|
| 2008.382 | An Open-Label Extension Phase of the Double-Blind, Placebo-Controlled, Dose-Escalation, Parallel-Group Studies to Evaluate the Efficacy and Safety of E2007 (perampanel) Given as Adjunctive Therapy in Subjects with Refractory Partial Seizures | Dr Kwan Patrick |
| 2003.293 | An Open-Label Extension Study to Assess the Safety and Tolerability of a 25mg Dose of SCH 420814 as Monotherapy in Subjects with Early Parkinson | Prof. Wong Ka Sing Lawrence |
| 2011.599 | An Open-Label Extension Study to Assess the Safety of GSK1605786A in Subjects with Crohn | Dr Ng Siew Chien |
| 2021.535 | An Open-Label Extension Study to Evaluate the Long-Term Safety, Tolerability, and Efficacy of Marstacimab Prophylaxis in Severe (Coagulation Factor Activity <1%) Hemophilia A Participants With or Without Inhibitors or Moderately Severe to Severe Hemophilia B Participants (Coagulation Factor Activity ≤2%) With or Without Inhibitors |
Dr. LEUNG Wing Kwan 梁永堃 |
| 2019.481 | AN OPEN-LABEL EXTENSION STUDY TO EVALUATE THE LONG-TERM SAFETY, TOLERABILITY, AND EFFICACY OF REGN3918 IN PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA | Dr. WONG Raymond Siu Ming |
| 2021.567 | An open-label extension study to investigate the long-term safety, tolerability, and efficacy of rozanolixizumab in study participants with persistent or chronic primary immune thrombocytopenia (ITP) |
Dr. WONG Raymond Siu Ming 王紹明 |
| 2002.411 | An Open-Label Extension Trial to Assess The Safety of Galantamine HBr in the Treatment of Vascular Dementia Revised : cre-2002.216-t, cre-2002.124-t | Prof. Wong Ka Sing Lawrence |
| 2005.300 | An Open-Label Follow-up Trial of the Efficacy and Safety of Chronic Administration of the Fixed Dose Combination of Telmisartan 80mg + Hydrochlorothiazide 25mg tablets Alone or in Combination with Other Antihypertensive Medications in Patients with Hypertension | Prof. Kong Pik Shan Alice |
| 2011.562 | An Open-Label Long-term Safety Extension Trial for Subjects with Systemic Lupus Erythematosus Who Have Completed Protocol AN-SLE3321 (PEARL-SC) | Professor Tam Lai-Shan |
| 2011.028 | An open-label multi-center study of erlotinib (Tarceva®) as first line therapy until and beyond RECIST progression in NSCLC patients who harbor EGFR mutations | Prof. MOK Tony Shu Kam |
| 2010.158 | An Open-Label Multicenter Extension Study to Determine Long Term Safety and Efficacy of Pregabalin (Lyrica) as Monotherapy in Patients with Partial Seizures | Dr. Kwan Patrick |
| 2005.197 | An Open-Label Multicenter Randomized Phase 3 Study Comparing the Combination of DOXIL_/CAELYX_ and YONDELIS | Prof. Yeo Winnie |
| 2007.247 | An Open-Label Multicenter Study Administering Lapatinib and Capecitabine (Xeloda) in Women with Advanced or Metastatic Breast Cancer | Prof. Yeo Winnie |
| 2023.312 | An Open-Label Phase 1b Study Evaluating the Safety, Tolerability, Immunogenicity and Antiviral Activity of Multiple Doses of CLB-3000 in Subjects with Chronic Hepatitis B | Prof. WONG Grace |
| 2007.241 | An Open-Label Phase I/II Study to Assess the Safety and Immunogenicity of Two Doses of a Vero Cell-Derived, Whole Virus Clade 2 H5N1 Influenza Vaccine in Healthy Volunteers Aged 21 to 45 Years | Prof. Hui SC David |
| 2016.165 | An open-label phase II study of pembrolizumab in East Asian patients with advanced/metastatic acral lentiginous melanoma |
Dr. LOONG Herbert 龍浩鋒 |
| 2010.457 | An Open-label Phase Ii Study of TK1258 as Neo-adjuvant Therapy in Patient with Muscle-invasive Bladder Cancer | Dr Chan Shu Yin Eddie |
| 2002.394 | An Open-Label Phase IIa Trial of Evaluating the Safety and Efficacy of EPO906 as Therapy in Patients with Advanced Local or Metastatic Gastric Cancer | Prof. Yeo Winnie |
| 2018.444 | An open-label pilot study of fecal microbiota transplant (FMT) to induce weight loss in obese subjects |
Prof. NG Siew Chien 黃秀娟教授 |
| 2007.242 | An Open-Label Prospective Trial to Explore the Tolerability, Safety and Efficacy of Flexibly Dosed Paliperidone ER in Subjects with Schizophrenia | Dr. Chung Wai Sau Dicky |
| 2021.134 | An open-label randomized controlled trial on convalescent plasma for treatment of severe COVID-19 infection |
Dr. LUI Grace C.Y. 雷頌恩 |
| 2015.607 | An Open-label Randomized Multinational Phase 3 Trial of Nivolumab versus Docetaxel in Previously Treated Subjects with Advanced or Metastatic Non-small Cell Lung Cancer |
Prof. MOK Tony Shu Kam 莫樹錦 |
| 2003.230 | An Open-Label Randomized Phase III Study of Intermittent Oral Capecitabine in Combination with Intravenous Oxaliplatin (Q3W) ("XELOX") versus Bolus and Continuous Infusion Fluorouracil/Intravenous Leucovorin with Intravenous Oxaliplatin (Q2W) ("FOLFOX-4") as First-Line Treatment for Patients with Metastatic Colorectal Cancer | Prof. Chan Tak Cheung Anthony |
| 2019.704 | An Open-Label Study in Adolescent and Adult Severe (Coagulation Factor Activity <1%) Hemophilia A Participants With or Without Inhibitors or Moderately Severe to Severe Hemophilia B Participants (Coagulation Factor Activity ≤2%) With or Without Inhibitors Comparing Standard Treatment to PF-06741086 Prophylaxis |
Prof. LI Chi Kong 李志光教授 |
| 2017.568 | An Open-Label Study of Brentuximab Vedotin+Adriamycin, Vinblastine, and Dacarbazine in Pediatric Patients With Advanced Stage Newly Diagnosed Hodgkin Lymphoma |
Prof. LI Chi Kong 李志光教授 |
| 2007.361 | An open-label study to evaluate the safety and efficacy of IMATINIB with chemotherapy in pediatric patients with Ph+/BCR-ABL+ acute lymphoblastic leukemia (Ph+ALL) | Dr. LI Chi Kong |
| 2012.034 | An Open-label study to investigate Deep Brain Stimulation over ventral capsule/ventral striatum area in the treatment of Resistant Obsessive Compulsive Disorder | Prof. POON Wai Sang |
| 2010.255 | An Open-label study to investigate Deep Brain Stimulation over verntal capsule/ventral striatum area in the treatment of Treatment Resistant Major Depressive Disorder | Prof., _x000D_Prof. Wing, _x000D_Poon Yun-kwok, _x000D_Wai-sang |
| 2012.357 | An open-label trial of 48-week peginterferon alfa-2a (PEGASYS) to assess the sustained response of chronic hepatitis B patients with HBeAg seroconversion on nucleot(s)ide analogue therapy | Prof. WONG Grace Lai Hung |
| 2013.016 | An open-label trial of 48-week peginterferon alfa-2a (PEGASYS) to assess the sustained response of chronic hepatitis B patients with HBeAg seroconversion on nucleot(s)ide analogue therapy | Dr.. Lai Moon Sing |
| 2012.539 | An open-label trial of 48-week peginterferon alfa-2a (PGEASYS) to assess the sustained response of chroinc hepatitis B patients with HBeAg seroconversion on nucleot(s)ide analogue therapy | Dr. HUI Aric Josun |
| 2002.459 | An Open-label, Long-term, Flexible-dose Study of Safety, Tolerability, and Therapeutic Response of PNU-95666E in Patients with Parkinson's Disease | Prof. Wong Ka Sing Lawrence |
| 2019.684 | An open-label, multi-center rollover protocol for continued characterization of safety and tolerability for subjects who have participated in a Novartis-sponsored spartalizumab study as single agent or in combination with other study treatments |
Prof. MA Brigette Buig Yue 馬碧如教授 |
| 2019.453 | An open-label, multi-center, Phase IV, roll-over study in patients with ALK positive malignancies who have completed a prior Novartis-sponsored ceritinib (LDK378) study and are judged by the investigator to benefit from continued treatment with ceritinib |
Dr. LOONG Herbert Ho Fung 龍浩鋒醫生 |
| 2012.451 | An Open-Label, Multi-Center, Single Arm Study to Evaluate the Safety and Tolerability of Intravenous Zanamivir in the Treatment of Hospitalized Adult, Adolescent and Pediatric Subjects with Confirmed Influenza Infection | Professor Leung Ting Fan |
| 2009.457 | An open-label, multi-center, three arm randomized, phase III study to compare the efficacy and safety of RO5072759 +chlorambucil (GClb), rituximab + chlorambucil (RClb) or chlorambucil (Clb) alone in previously untreated CLL patients with comorbidities | Dr. WONG Raymond Siu Ming |
| 2005.365 | An Open-Label, Multi-Centre and Long-Term Extension Study to Evaluate the Safety and Tolerability of Oral Tesaglitazar 1mg in Patients with Type 2 Diabetes Mellitus (GALLEX 1) | Prof. Chan CN Juliana |
| 2011.607 | An Open-Label, Multicenter Evaluation of Safety, Pharmacokinetics, and Efficacy of Recombinant Coagulation Factor IX Fc Fusion Protein, BIIB029, in the Prevention and Treatment of Bleeding Episodes in Pediatric Subjects With Hemophilia B | Dr. Li Chi Kong |
| 2011.606 | An Open-Label, Multicenter Evaluation of Safety, Pharmacokinetics, and Efficacy of Recombinant Coagulation Factor VIII Fc Fusion Protein, BIIB031, in the Prevention and Treatment of Bleeding Episodes in Pediatric Subjects With Hemophilia A | Dr. Li Chi Kong |
| 2011.479 | An Open-Label, Multicenter Evaluation of the Long-Term Safety and Efficacy of Recombinant Human Coagulation Factor IX Fusion Protein (rFIXFc) in the Prevention and Treatment of Bleeding Episodes in Previously Treated Subjects With Hemophilia B | Dr. WONG Raymond Siu Ming |
| 2013.047 | An Open-Label, Multicenter Evaluation of the Long-Term Safety and Efficacy of Recombinant Human Coagulation Factor VIII Fusion Protein (rFVIIIFc) in the Prevention and Treatment of Bleeding Episodes in Previously Treated Subjects With Hemophilia A | Dr. LI Chi Kong |
| 2011.538 | An Open-Label, Multicenter Evaluation of the Long-Term Safety and Efficacy of Recombinant Human Coagulation Factor VIII Fusion Protein (rFVIIIFc) in the Prevention and Treatment of Bleeding Episodes in Previously Treated Subjects With Hemophilia A | Dr. WONG Raymond Siu Ming |
| 2021.630 | An Open-Label, Multicenter Phase 1b/2 Study of Nanatinostat and Valganciclovir in Patients with Advanced Epstein-Barr Virus- Positive (EBV+) Solid Tumors and in Combination with Pembrolizumab in Patients with Recurrent/Metastatic Nasopharyngeal Carcinoma | Prof. MA Brigette Buig Yue |
| 2009.412 | An open-label, multicenter phase II study to compare the efficacy and safety of RAD001 as first-line followed by second-line sunitinib versus sunitinib as first-line followed by second-line RAD001 in the treatment of patients with metastatic renal cell carcinoma | Dr. Ho Wing Ming |
| 2012.419 | An Open-label, Multicenter Study to Evaluate the Safety of Long-term Treatment with Siltuximab in Subjects with Multicentric Castleman's Disease | Dr. WONG Raymond Siu Ming |
| 2011.539 | An Open-Label, Multicenter, Follow-Up Study to Evaluate the Long-Term Safety and Efficacy of Brivaracetam Used as Adjunctive Treatment in Subjects Aged 16 Years or Older with Epilepsy | Dr. Kwan Patrick |
| 2008.095 | An Open-Label, Multicenter, Follow-up Trial to Evaluate Long-Term Safety and Efficacy of Brivaracetam (ucb 34714) Used as Adjunctive Treatment at A Flexible Dose Up to A Maximum of 200 mg/ day in Subjects Aged 16 Years or Older Suffering From Epilepsy | Dr. KWAN Patrick |
| 2016.076 | An Open-Label, Multicenter, Global Phase II Basket Study of Entrectinib for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors that Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements |
Dr. LOONG Herbert Ho Fung 龍浩鋒 |
| 2024.425 | An Open-Label, Multicenter, Phase 1 Study of AN4005 in Patients with Advanced Tumors | Dr. LOONG Herbert Ho Fung |
| 2016.493 | An Open-Label, Multicenter, Phase 1 Study with Expansion Cohorts of Ramucirumab or Necitumumab in Combination with Osimertinib in Patients with Advanced T790M-Positive EGFR-Mutant Non-Small Cell Lung Cancer after Progression on First-Line EGFR TKI Therapy |
Dr. LOONG Herbert Ho Fung 龍浩鋒 |
Page 56 of 254.